Forte Biosciences vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Forte Biosciences Inc (FBRX)

Q3 202621 Jul – 27 Aug 2026

▲2▼1

Forte acquired by argenx for $77/share after positive vitiligo data

Acquisition by argenx Forte Biosciences was acquired by argenx for $77 per share in cash, about $2.2 billion, an 86% premium. The deal closed August 27, 2026, giving shareholders the cash price.
This is the main event that drove FBRX's price in Q3 2026.
Positive Phase 1 vitiligo data Positive Phase 1 vitiligo data for FB102 made Forte an attractive takeover target, leading to the argenx acquisition and folding FB102 into argenx's immunology pipeline.
The clinical data was the catalyst that attracted the acquirer.
Investor-rights investigations Several investor-rights law firms are investigating whether $77 is fair, citing possible insider benefits and deal terms discouraging rival bids. Such probes rarely change an agreed cash deal.
This is the main risk that could affect the deal price or timing.
End of standalone trading With the buyout complete, FBRX no longer trades on its own clinical results. The stock's price is now tied to the cash deal, and future performance depends on argenx.
This marks the end of FBRX as an independent company, a key structural change.

August 202621 Jul – 27 Aug 2026

▲2

Forte Biosciences bought by argenx for $77 a share in cash

argenx agrees to buy Forte for $77/share cash argenx is acquiring Forte Biosciences for $77.00 per share in cash, a deal worth about $2.2 billion. That price is the main thing setting FBRX's value now: once a cash buyout is agreed, the stock tends to trade near the offer rather than on its own drug news.
The agreed cash buyout is the single force that now determines FBRX's price.
Deal closes, ending FBRX as a standalone stock argenx completed the acquisition on August 27, 2026, folding Forte's FB102 antibody into its immunology pipeline. Shareholders get the $77 cash per share. With the deal done, FBRX no longer trades on its own clinical results — its story is now argenx's pipeline plans.
Completion is the final event that locks in the buyout outcome for shareholders.
Law firms question whether $77 is fair Several investor-rights law firms are investigating whether the $77 sale is fair, citing possible insider benefits and deal terms that may discourage rival bids. They may seek a higher price or more disclosure. This creates some chance of a bump, but such probes rarely change an agreed cash deal.
It is the main counterweight to the buyout price and could affect what shareholders ultimately receive.

Latest21 Jul – 27 Aug 2026

▲2

Forte Biosciences bought by argenx for $77 a share in cash

argenx agrees to buy Forte for $77/share cash argenx is acquiring Forte Biosciences for $77.00 per share in cash, a deal worth about $2.2 billion. That price is the main thing setting FBRX's value now: once a cash buyout is agreed, the stock tends to trade near the offer rather than on its own drug news.
The agreed cash buyout is the single force that now determines FBRX's price.
Deal closes, ending FBRX as a standalone stock argenx completed the acquisition on August 27, 2026, folding Forte's FB102 antibody into its immunology pipeline. Shareholders get the $77 cash per share. With the deal done, FBRX no longer trades on its own clinical results — its story is now argenx's pipeline plans.
Completion is the final event that locks in the buyout outcome for shareholders.
Law firms question whether $77 is fair Several investor-rights law firms are investigating whether the $77 sale is fair, citing possible insider benefits and deal terms that may discourage rival bids. They may seek a higher price or more disclosure. This creates some chance of a bump, but such probes rarely change an agreed cash deal.
It is the main counterweight to the buyout price and could affect what shareholders ultimately receive.

July 202623 Jul – 29 Jul 2026

▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.
This is the single new event that explains the period's move and sets the stock's value near the offer price.
Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.
It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.
Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.
It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

23 Jul – 29 Jul 2026

▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.
This is the single new event that explains the period's move and sets the stock's value near the offer price.
Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.
It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.
Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.
It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

Abcellera Biologics Inc (ABCL)

Q3 202617 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 202617 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest17 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.